HIV infection in adolescents

Sexually transmitted diseases Main Page
	AIDS Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating AIDS from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
HIV Opportunistic Infections
HIV Coinfections
HIV and Pregnancy
HIV Infection in Infants
Diagnosis
Diagnostic Study of Choice
AIDS Case Definition
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Nutrition
Drug Resistance
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies HIV Vaccine
Case Studies
Case #1
HIV infection in adolescents On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of HIV infection in adolescents All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on HIV infection in adolescents
CDC on HIV infection in adolescents
HIV infection in adolescents in the news
Blogs on HIV infection in adolescents
Directions to Hospitals Treating AIDS
Risk calculators and risk factors for HIV infection in adolescents

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

An increasing number of HIV-infected children who acquired HIV infection through perinatal transmission are now surviving into adolescence. They generally have had a long clinical course and extensive ARV treatment history.^[1] Adolescents with behaviorally acquired infection (i.e., infection acquired via sexual activity or intravenous substance use) generally follow a clinical course similar to that in adults. Because behaviorally infected adolescents are at an early stage of HIV infection, they are potential candidates for early intervention and treatment.

Treatment

Dosing

Many ARV medications (e.g., abacavir, emtricitabine, lamivudine, tenofovir, and some protease inhibitors [PIs]) are administered to children at higher weight- or surface area-based doses than would be predicted by direct scaling of adult doses, based upon reported PK data indicating more rapid drug clearance in children.
Continued use of these pediatric weight- or surface area-based doses as a child grows during adolescence can result in medication doses that are higher than the usual adult doses.
Many factors may affect the transition from pediatric to adult doses. In addition to toxicity, pill burden, adherence, and virologic and immunologic parameters, factors may include social determinants, such as housing, family support, employment, and recent discharge from the foster care system.

Specific issues in antiretroviral therapy for HIV-infected adolescents

Adolescent Contraception

Reference

↑ Van Dyke RB, Patel K, Siberry GK, Burchett SK, Spector SA, Chernoff MC, Read JS, Mofenson LM, Seage GR (2011). "Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes". Journal of Acquired Immune Deficiency Syndromes (1999). 57 (2): 165–73. doi:10.1097/QAI.0b013e318215c7b1. PMID 21407086. Retrieved 2012-06-04. Unknown parameter |month= ignored (help)

[pmid21407086-1] Van Dyke RB, Patel K, Siberry GK, Burchett SK, Spector SA, Chernoff MC, Read JS, Mofenson LM, Seage GR (2011). "Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes". Journal of Acquired Immune Deficiency Syndromes (1999). 57 (2): 165–73. doi:10.1097/QAI.0b013e318215c7b1. PMID 21407086. Retrieved 2012-06-04. Unknown parameter |month= ignored (help)

[1]